Abacavir compared to protease inhibitors as part of HAART regimens for treatment of HIV infection: Patient satisfaction and implications for adherence

AIDS Patient Care and STDs

Volumn 19, Issue 1, 2005, Pages 9-18

  Jordan, J ^a   Cahn, P ^b   Goebel, F ^c   Matheron, S ^d   Bradley, C ^e   Woodcock, A ^e  

^a GLAXOSMITHKLINE   (United States)

^b FUNDACIÓN HUÉSPED   (Argentina)

^c UNIVERSITY OF MUNICH   (Germany)

^d BICHAT HOSPITAL   (France)

^e UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; INDINAVIR; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG DOSE REGIMEN; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUESTIONNAIRE; SIDE EFFECT;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS; DIDEOXYNUCLEOSIDES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PATIENT SATISFACTION; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 12844283246     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2005.19.9     Document Type: Article

References (27)

1. CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet 2000;355:1158-1159.
2. AIDSinfo. Antiretroviral drugs: Overview of drugs. US Department of Health and Human Services. aidsinfo.nih.gov/drugs. (Last accessed April 2003).
3. Eraker S, Kirscht J, Becker M. Understanding and improving patient compliance. Ann Intern Med 1984;100:258-268.
4. Ickovics J, Meisler A. Adherence to AIDS clinical trials: A framework for clinical research and clinical care. J Clin Epidemiol 1997;50:385-391.
5. Stone VE, Hogan JW, Schuman P, et al. Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: Survey of women in the HER study. J Acquir Immun Defic Syndr 2001;28:124-131.
6. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS 2001;15:1369-1377.
7. Bartlett J, DeMasi R, Quinn J, et al. Correlation between antiretroviral pill burden and durability of virologic response: a systemic overview [Abstract ThPeB44998]. Presented at XIII International Conference on AIDS; Durban, South Africa: 2000.
8. Brook MG, Dale A, Tomlinson D, Waterworth C, Daniels D, Forster G. Adherence to highly active antiretroviral therapy in the real world: Experience of twelve English HIV units. AIDS Patient Care STDS 2001;15:491-494.
9. Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med 2002;17:756-765.
10. Jordan J, Cahn P, Vibhagool A. Predictors of adherence and efficacy in HIV-1 infected patients treated with abacavir plus Combivir or indinavir plus Combivir: Final 48-week data from CNA3014. Presented at 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA; 2002; February 24-28, 2002; 543T.
11. Roberts KJ. Physician-patient relationships, patient satisfaction, and antiretroviral medication adherence among HIV-infected adults attending a public health clinic. AIDS Patient Care STDS 2002;16:43-50.
12. Woodcock A, Bradley C. Validation of the HIV treatment satisfaction questionnaire (HIVTSQ). Qual Life Res 2001;10:517-531.
13. Hudak PL, Wright JG. The characteristics of patient satisfaction measures. Spine 2000;25:3167-3177.
14. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
15. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JSG. Adherence to triple therapy and viral load response [letter]. J Acquire Immune Defic Syndr 2000;23:360-361.
16. Vibhagool A. Abacavir/Combivir is comparable to indinavir/Combivir in HIV-1 infected antiretroviral therapy naïve adults: results of a 48-week open label study [Abstract 063]. Presented at 1st IAS Conference of HIV Pathogenesis and Treatment, Buenos Aires, Argentina: July 8-11, 2001.
17. Clumeck N, Goebel F, Rozenbaum W, et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001;15:1517-1526.
18. Matheron S, Descamps D, Boue F, et al. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinivir as firstline therapy in HIV-1-infected adults: a randomized trial. Antiviral Ther 2003;8:73-81.
19. Ley P. Satisfaction, compliance, and communication. Br J Clin Psych 1982;21:241-254.
20. Katzenstein DA. Adherence as a particular issue with protease inhibitors. J Assoc Nurses AIDS Care 1997;(Suppl 8):10-17.
21. Casado JL, Sabido R, Perez-Elias MJ, et al. Percentage of adherence correlates with the risk of protease inhibitor (PI) treatment failure in HIV-infected patients. Antivir Ther 1999;4:157-161.
22. Friedland GH, Williams A. Attaining higher goals in HIV treatment: the central importance of adherence. AIDS 1999;13(Suppl 1):S61-72.
23. Pradier C, Carrieri P, Bentz L, et al. Impact of short-term adherence on virological and immunological success of HAART: A case study among French HIV-infected IDUs. Int J STD AIDS 2001;12:324-328.
24. Le Moing V, Chene G, Carrieri MP, et al. Predictors of virological rebound in HIV-1 infected patients initiating a protease inhibitor-containing regimen. AIDS 2002;16:21-29.
25. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clin Infect Dis 2001;33:1417-1423.
26. Melbourne KM, Geletko SM, Brown SL, et al. Medication adherence in patients with HIV infection: a comparison of two measurement methods. AIDS Reader 1999;9:329-338.
27. Gulick RM, Ribaudo HJ, Shikuma CM, et al. ACTG 5095: A comparative study of three protease inhibitor sparing antitretroviral regimens for the intial treatment of HIV infection. N Engl J Med 2004;350:1850.